Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, called Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained to form two loops that stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity, and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches. Bicycle has a novel and proprietary phage display screening platform that we use to identify Bicycles in an efficient manner. Bicycle’s internal programs are focused on oncology indications with high unmet medical need. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) that is designed to target tumors that express MT1-MMP. BT1718 is being investigated for safety, tolerability and efficacy in an ongoing Phase I/IIa clinical trial in collaboration with, and fully funded by, the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated a Company-sponsored Phase I/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA.